CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOACaptura de pantalla 2022 09 14 a las 10.27.10    

Genome Instability and Cancer Predisposition

Research Summary:

Genome stability is essential for survival in every organism allowing cells to faithfully transmit genetic information from generation to generation. Preserving genome stability is also critical to prevent several human diseases including cancer.

Our lab interrogates the cellular mechanisms (DNA repair pathways) deployed to preserve genome integrity with a particular focus on the high-fidelity DNA repair mechanism homologous recombination (HR) and the breast cancer susceptibility protein BRCA2 involved in this process, as a model.

Mutations in BRCA2 predispose to breast and ovarian cancer with high penetrance and they are also linked to other types of cancer such as prostate and pancreatic cancer as well as the cancer-predisposing syndrome Fanconi anemia. Thus, with this model, we hope to shed light on the link between BRCA2 mutations, genome instability, and cancer predisposition.

General Questions:

  • What are the different mechanisms that BRCA2 (and its partner proteins) use to promote HR in the context of DNA double-strand breaks (DSB) and replication stress?
  • How are the chromosome integrity mechanisms of the cell coordinated through the cell cycle?
  • Which mutations in BRCA2 predispose to cancer and why?

Our tools:

We use a combination of biochemistry, cell biology, “omics” techniques, and BRCA2 missense variants of unknown significance (VUS) identified in breast cancer patients as a genetic tool.

Image

Figure 1. Schematic representation of the possible impact of the functional characterization of BRCA2 VUS detected in breast cancer patients on function discovery. In addition to the better understanding of the mechanisms of genome maintenance, these novel functions may have important clinical implications for the reclassification of VUS and therefore for the genetic counseling of cancer patients and their families. In turn, these new activities of BRCA2 or new partners may lead to the discovery of vulnerabilities that could be exploited for treatment. DSBs: DNA double-strand breaks; RNAPII, RNA polymerase II. Figure created with BioRender.com.

With these approaches, we expect to shed light on the multiple roles of BRCA2 on chromosome integrity but also help reclassify BRCA2 VUS into pathogenic or benign. Ultimately, we hope our research will open new therapeutic avenues (Figure 1).

To enquire about job opportunities in our lab look for the specific ads in Others contact directly Aura Carreira at acarreira@cbm.csic.es

https://conexion-cancer.csic.es/

Twitter: @auracarreiralab

Image


* For external calls please dial 34 91196 followed by the extension number
Last nameNameLaboratoryExt.*e-mailProfessional category
Álvaro ArandaLucía3224827 lucia.alvaro(at)cbm.csic.esTitulado Sup. Actividades Tecn. y Prof.GP1
Bellido CarrerasNatividad3224827nbellido(at)cbm.csic.esM3 66,66%
Carreira MorenoAura3224497 acarreira(at)cbm.csic.esE. Investigadores Científicos de Organismos Públicos
Chaaban Rady3224827Estudiante
Escalona NogueroCarmen3224827cescalona(at)cbm.csic.esM2 66,66%
Gómez EscuderoJesús3224497jesus.gomez(at)cbm.csic.esDoctor FC3 indef.
Hernando HerreraIrene3224827irene.hernando(at)cbm.csic.esM3 Predoc.formación
Sridhara S R Chaitanya3224827srchaitanya(at)cbm.csic.esM3

  • Alvaro-Aranda L, Petitalot A, Djeghmoum Y, Panigada D, Singh JK, Ehlén Å, Vugic D, Martin C, Miron S, Contreras-Perez A, Nhiri N, Boucherit V, Lafitte P, Dumoulin I, Rouleau E, Jacquet E, Feliubadaló L, Del Valle J, Stoppa-Lyonnet D, Zinn-Justin S, Lázaro C, Caputo SM, Carreira A. The BRCA2 R2645G variant increases DNA binding and induces hyper-recombination. Nucleic Acids Res. 2023 Dec 24;. doi: 10.1093/nar/gkad1222.
  • Mishra AP, Hartford S, Chittela RK, Sahu S, Kharat SS, Alvaro-Aranda L, Contreras-Perez A, Sullivan T, Martin BK, Albaugh M, Southon E, Burkett S, Karim B, Carreira A, Tessarollo L, Sharan SK. Characterization of BRCA2 R3052Q variant in mice supports its functional impact as a low-risk variant. Cell Death Dis. 2023 Nov 18;14(11):753. doi: 10.1038/s41419-023-06289-8.
  • Minello A, Carreira A. BRCA1/2 Haploinsufficiency: Exploring the Impact of Losing one Allele. J Mol Biol. 2023 Sep 14;:168277. doi: 10.1016/j.jmb.2023.168277.  Review.
  • Vugic D, Dumoulin I, Martin C, Minello A, Alvaro-Aranda L, Gomez-Escudero J, Chaaban R, Lebdy R, von Nicolai C, Boucherit V, Ribeyre C, Constantinou A, Carreira A. (2023) Replication gap suppression depends on the double-strand DNA binding activity of BRCA2. Nat Commun. 14(1):446.
  • Sessa G, Ehlén Å, von Nicolai C, Carreira A (2021). Missense Variants of Uncertain Significance: A Powerful Genetic Tool for Function Discovery with Clinical Implications. Cancers (Basel) 13(15):3719.  
  • Julien M, Ghouil R, Petitalot A, Caputo SM, Carreira A, Zinn-Justin S. (2021). Intrinsic Disorder and Phosphorylation in BRCA2 Facilitate Tight Regulation of Multiple Conserved Binding Events. Biomolecules; 11(7):1060. 
  • Ehlén Å, Sessa G, Zinn-Justin S, Carreira A. (2021). The phospho-dependent role of BRCA2 on the maintenance of chromosome integrity. Cell Cycle; 20(8):731-741. 
  • Sessa G*, Gómez-González B*, Silva S, Pérez-Calero C, Beaurepere R, Barroso S, Martineau S, Martin C, Ehlén Å, Martínez JS, Lombard B, Loew D, Vagner S, Aguilera A#Carreira A#. (* equal contribution, # corresponding author) (2021) BRCA2 promotes DNA-RNA hybrid resolution by DDX5 helicase at DNA breaks to facilitate their repair. EMBO J; 40(7):e106018.
  • D Vugic, Å Ehlén, A Carreira (2021): Book: Homologous Recombination: Monitoring Homologous Recombination Activity in Human Cells Methods in Molecular Biology 2153, 115-126 Humana Press Springer ISBN 978-1-0716-0643-8
  • Ehlén Å, Martin C*, Julien M*, Miron S*, Theillet FX, Ropars V, Sessa G, Beaurepere R, Boucherit V, Duchambon P, El Marjou A, Zinn-Justin S#, Carreira A#. (2020) (* equal contribution, #corresponding author) Proper chromosome alignment depends on BRCA2 phosphorylation by PLK1. Nature Commun.;11(1) 1-21
  • Nicolai C, Ehlén Å, Martinez JS, Carreira A (2018): Chapter 19. Dissecting the Recombination Mediator Activity of BRCA2 Using Biochemical Methods. Methods in Enzymology v600 479-511 Academic Press Elsevier ISBN: 978-0-12-814429-9
  • Shimelis H*, Mesman RLS*, von Nicolai C*, Ehlén Å*, Guidugli L, Martin C, Calléja FMGR, Meeks H, Hallberg E, Hinton J, Lilyquist J, Hu C, Aalfs CM, Aittomäki K, Andrulis I, Anton-Culver H, Arndt V, Beckmann MW, Benitez J, Bogdanova NV, Bojesen SE, Bolla MK, Borresen-Dale AL, Brauch H, Brennan P, Brenner H, Broeks A, Brouwers B, Brüning T, Burwinkel B, Chang-Claude J, Chenevix-Trench G, Cheng CY, Choi JY, Collée JM, Cox A, Cross SS, Czene K, Darabi H, Dennis J, Dörk T, Dos-Santos-Silva I, Dunning AM, Fasching PA, Figueroa J, Flyger H, García-Closas M, Giles GG, Glendon G, Guénel P, Haiman CA, Hall P, Hamann U, Hartman M, Hogervorst FB, Hollestelle A, Hopper JL, Ito H, Jakubowska A, Kang D, Kosma VM, Kristensen V, Lai KN, Lambrechts D, Marchand LL, Li J, Lindblom A, Lophatananon A, Lubinski J, Machackova E, Mannermaa A, Margolin S, Marme F, Matsuo K, Miao H, Michailidou K, Milne RL, Muir K, Neuhausen SL, Nevanlinna H, Olson JE, Olswold C, Oosterwijk JJC, Osorio A, Peterlongo P, Peto J, Pharoah PDP, Pylkäs K, Radice P, Rashid MU, Rhenius V, Rudolph A, Sangrajrang S, Sawyer EJ, Schmidt MK, Schoemaker MJ, Seynaeve C, Shah M, Shen CY, Shrubsole M, Shu XO, Slager S, Southey MC, Stram DO, Swerdlow A, Teo SH, Tomlinson I, Torres D, Truong T, van Asperen CJ, van der Kolk LE, Wang Q, Winqvist R, Wu AH, Yu JC, Zheng W, Zheng Y, Leary J, Walker L, Foretova L, Fostira F, Claes KBM, Varesco L, Moghadasi S, Easton DF, Spurdle A, Devilee P, Vrieling H, Monteiro ANA, Goldgar DE*, Carreira A*, Vreeswijk MPG*, Couch FJ*:  (2017) (* equal contribution) BRCA2 hypomorphic missense variants confer moderate risks of breast cancer. Cancer Res. 77(11): 2789-2799.
  • Nicolai C, Ehlén Å, Martin C, Zhang X, Carreira A. (2016). A second DNA binding site in human BRCA2 promotes homologous recombination. Nature Commun., 7(1) 1-8.
  • Martinez JS*, von Nicolai C*, Kim T, Ehlén Å, Mazin AV, Kowalczykowski SC#, and Carreira A# (* equal contribution, #corresponding author) (2016) BRCA2 regulates DMC1-mediated recombination through the BRC repeats. Proc. Natl. Acad. Sci. USA; 113(13):3515-20.
  • Martinez JS, Baldeyron C, Carreira A. (2015). Molding BRCA2 through its interacting partners. Cell Cycle;14(21):3389-95
  • Guidugli L*, Carreira A*, Caputo SM*, Ehlén Å, Galli A, Monteiro AN, Neuhausen SL, Hansen TV, Couch FJ, Vreeswijk MP; ENIGMA consortium. (2014) (*equal contribution) Functional assays for analysis of variants of uncertain significance in BRCA2. Hum Mutat. 35(2):151-64.
  • Carreira, A., and Kowalczykowski, S. C. (2011) Two classes of BRC repeats in BRCA2 promote RAD51 nucleoprotein filament function by distinct mechanisms. Proc. Natl. Acad. Sci. USA. 108(26):10448-53.
  • Jensen, R., Carreira A., and Kowalczykowski S. C. (2010). Purified human BRCA2 stimulates RAD51 mediated recombination. Nature. 467(7316): 678-83.
  • Carreira A, Hilario J, Amitani I, Baskin RJ, Shivji MK, Venkitaraman AR, Kowalczykowski SC. (2009) The BRC repeats of BRCA2 modulate the DNA-binding selectivity of RAD51. Cell 136(6):1032-43.
  • Carreira A, Kowalczykowski SC. (2009) BRCA2: Shining light on the regulation of DNA-binding selectivity by RAD51. Cell Cycle. 8(21):3445-7.
  • Anna Minello: Shedding light on the mechanisms of tumor formation linked to BRCA2 using two known pathogenic variants (2023) PhD with honors. Paris-Saclay University, France
  • Isaac Dumoulin: Functional interaction between BRCA2 and a novel partner in the maintenance of genome integrity (2022) PhD with honors. Paris-Saclay University, France
  • Domagoj Vugic: Interplay between the two DNA binding domains of BRCA2 (2021) PhD with honors. Paris-Saclay University, France
  • Gaetana Sessa: Role of the interaction of BRCA2 and DDX5 in the DNA damage response (2020). PhD with honors. Paris-Saclay University, France
  • Catharina von Nicolai: Characterization of a novel DNA binding domain in the N-terminus of BRCA2 (2016). PhD with honors. Paris-Saclay University, France

 

logo2

logo3

logo3

AECC

WCR Logo Blue RGB copy

Logo AEI sin fondo

NOTE! This site uses cookies and similar technologies.

If you not change browser settings, you agree to it. Learn more

I understand

COOKIES POLICY

What are cookies?

A cookie is a file that is downloaded to your computer when you access certain web pages. Cookies allow a web page, among other things, to store and retrieve information about the browsing habits of a user or their equipment and, depending on the information they contain and the way they use their equipment, they can be used to recognize the user.

Types of cookies

Classification of cookies is made according to a series of categories. However, it is necessary to take into account that the same cookie can be included in more than one category.

  1. Cookies according to the entity that manages them

    Depending on the entity that manages the computer or domain from which the cookies are sent and treat the data obtained, we can distinguish:

    • Own cookies: those that are sent to the user's terminal equipment from a computer or domain managed by the editor itself and from which the service requested by the user is provided.
    • Third party cookies: those that are sent to the user's terminal equipment from a computer or domain that is not managed by the publisher, but by another entity that processes the data obtained through the cookies. When cookies are installed from a computer or domain managed by the publisher itself, but the information collected through them is managed by a third party, they cannot be considered as own cookies.

  2. Cookies according to the period of time they remain activated

    Depending on the length of time that they remain activated in the terminal equipment, we can distinguish:

    • Session cookies: type of cookies designed to collect and store data while the user accesses a web page. They are usually used to store information that only is kept to provide the service requested by the user on a single occasion (e.g. a list of products purchased).
    • Persistent cookies: type of cookies in which the data is still stored in the terminal and can be accessed and processed during a period defined by the person responsible for the cookie, which can range from a few minutes to several years.

  3. Cookies according to their purpose

    Depending on the purpose for which the data obtained through cookies are processed, we can distinguish between:

    • Technical cookies: those that allow the user to navigate through a web page, platform or application and the use of different options or services that exist in it, such as controlling traffic and data communication, identifying the session, access to restricted access parts, remember the elements that make up an order, perform the purchase process of an order, make a registration or participation in an event, use security elements during navigation, store content for the broadcast videos or sound or share content through social networks.
    • Personalization cookies: those that allow the user to access the service with some predefined general characteristics based on a series of criteria in the user's terminal, such as the language, the type of browser through which the user accesses the service, the regional configuration from where you access the service, etc.
    • Analytical cookies: those that allow the person responsible for them to monitor and analyse the behaviour of the users of the websites to which they are linked. The information collected through this type of cookies is used in the measurement of the activity of the websites, applications or platforms, and for the elaboration of navigation profiles of the users of said sites, applications and platforms, in order to introduce improvements in the analysis of the data of use made by the users of the service.

Cookies used on our website

The CBMSO website uses Google Analytics. Google Analytics is a simple and easy to use tool that helps website owners to measure how users interact with the content of the site. You can consult more information about the cookies used by Google Analitycs in this link.

Acceptance of the Cookies Policy

The CBMSO assumes that you accept the use of cookies if you continue browsing, considering that it is a conscious and positive action from which the user's consent is inferred. In this regard, you are previously informed that such behaviour will be interpreted that you accept the installation and use of cookies.

Knowing this information, it is possible to carry out the following actions:

  • Accept cookies: if the user presses the acceptance button, this warning will not be displayed again when accessing any page of the portal.
  • Review the cookies policy: the user can access to this page in which the use of cookies is detailed, as well as links to modify the browser settings.

How to modify the configuration of cookies

Using your browser you can restrict, block or delete cookies from any web page. In each browser the process is different, here we show you links on this particular of the most used browsers:

fondosocialeuropeo-300px.png
Ministerio-de-Ciencia-e-Innovacin-600px.png
Comunidad-de-Madrid-600Bpx.png
agenda20-30-600px.png
fundacion-areces600px0710.png
LOGO_ERC.jpg
hrexcellence.jpg
worldwidecancerresearch-600px0710.png
aecc-600tpx.png
bbva-fund-400.png
Niemann-Pick-400px.png
wilderfund-400px.png
AliciaKoplowitz-400px.png
la-caixa-fund-600px.png
inocente-inocente-600px.png
cure-alzheimers-fund-600px.png
citrin-foundation.png
tatiana-fund02-600bpx1.png
campus-excelencia-600x400px.png
fundacion-uno-entre-cien-mil-v02.png